However, this percentage could increase to 71.43%, considering that ESR1 (2.86%), ERBB4 (2.86%), and PIK3CA (8.57%) are not actionable genes in lung cancer (Figure 2G). This evidence concerns the gene ERBB4 and lung carcinoma.